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Summary Expression of the p53, the epidermal growth factor receptor (EGFr; c-erbB-1) and c-erbB-2
proteins was studied in 82 patients with primary transitional cell carcinoma of the bladder using an
immuno-histochemical method. Strong or moderate staining was found in 18% of tumours for p53 with
weaker staining in a further 36% giving a total of 54% of tumours stained for p53. Strong staining was found
in 15% of tumours for c-erbB-2 and in 31% for the EGFr. Tumours invading the bladder muscle were
significantly more likely to be strongly stained positively for p53 and/or EGFr compared with superficial
tumours: only 15% of invasive tumours were stained negatively for both p53 and EGFr. No statistical
association was found between p53 and EGFr expression. Weakly positive associations were found between
the expression ofc-erbB-2 and p53 and between muscle invasive tumours and increased expression ofc-erbB-2.
Alterations in the expression of p53, c-erbB-1 and c-erbB-2 were found frequently in human transitional cell
carcinoma of the urinary bladder and may be of clinical use in defining patient sub-groups of differing
prognosis.
p53 is a 393 amino-acid nucleo-phosphoprotein first identi-
fied as a result of binding to the large T antigen of the DNA
virus, SV40 (Lane & Crawford, 1979). The p53 gene product
binds strongly to the alpha subunit of DNA polymerase
(Gannon & Lane, 1987), and E1B antigen of adenovirus and
the E6 antigen of polyoma virus. It is a candidate gene for
the control of cellular proliferation (Jenkins & Sturzbecher,
1988).The human gene is located on the short arm of
chromosome 17 (Miller et al., 1986) which is a common site
for allelic deletions in human tumours, often being accom-
panied by mutations of the remaining allele (Baker et al.,
1989; Nigro et al., 1989; Takahashi et al., 1989; Thompson et
al., 1990). Transfection studies have shown that the wild type
protein is able to suppress cell proliferation and transforma-
tion (Finlay et al., 1989; Mercer et al., 1990). However,
cooperation has been demonstrated between mutant p53 and
mutant ras genes in cellular transformation (Parada et al.,
1984; Hinds et al., 1989) and transgenic mice carrying mutant
p53 are at increased risk of malignancy (Lavigueur et al.,
1989). Initially, these data suggested that p53 may function
as a tumour suppressor gene, but it now seems likely that
mutations in p53 may also cause it to act as an oncogene
under certain circumstances. The p53 protein can undergo
self-oligomerisation (Kraiss et al., 1988). It has been pro-
posed that in cells with a single allelic mutation of p53, the
mutated p53 which has a significantly increased half-life,
oligomerises and inactivates the wild type protein. In addi-
tion, the mutated p53 product does not bind to large T
antigen and unlike normal p53 (Braithwaite et al., 1987) does
not inhibit SV40 replication.
The c-erbB-2 gene encodes a membrane bound glyco-
protein which has sequence similarity with the epidermal
growth factor receptor (c-erbB-1 protein). Amplification and
over-expression of this protein in carcinomas of the breast
and ovary (Barnes, 1989; Slamon et al., 1989) is associated
with an inferior prognosis. The function of c-erbB-2 remains
uncertain, although it is thought possibly to function as a
growth factor receptor for an unidentified ligand.
Increased expression of the epidermal growth factor recep-
tor (EGFr) is found in certain bladder (Neal et al., 1985,
1990) and breast carcinomas (Sainsbury et al., 1987; Lewis et
al., 1990). In breast carcinoma, a significant association has
been found between p53 and the EGFr (Cattoretti et al.,
1988). In view of these findings and previous observations
that increased expression of the EGFr is of potential prog-
nostic significance in human bladder cancer (Neal et al.,
1990), we have carried out a study of p53, the EGFr and
c-erbB-2 in human bladder cancer.
Patients
Eighty-two patients (56 M; 26 F; mean age 69 ± 10 years)
with newly diagnosed primary transitional cell carcinomas of
the urinary bladder were studied. Tumour samples were
taken by means of cystoscopic resection, the samples were
placed in ice-cold saline and were urgently frozen and stored
in liquid nitrogen. The tumours were staged by examination
under anaesthesia (UICC, 1978) and according to the pre-
sence of invasion of lamina propria (pTl) or its absence
(pTa) or invasion of detrusor muscle (T2-T4). In addition,
paraffin embedded sections of each tumour were prepared
and tumour grade was assessed.
Forty-eight patients had superficial tumours (pTa and pTl;
42 moderately differentiated tumours and six poorly differ-
entiated tumours) and 33 had muscle invasive disease (six
moderately differentiated; 27 poorly differentiated tumours).
Tumour category was not assigned to one poorly differ-
entiated tumour.
Methods
Frozen sections were cut at 5 ts, air-dried and fixed in acetone
for 10 min. The protein products of p53, the EGFr and
c-erbB-2 were identified by means of an indirect immunoper-
oxidase technique using the following monoclonal antibodies.
PAb240 recognises an evolutionarily conserved epitope on
the p53 protein lying between amino acids 156-214 on
murine p53 and it is highly specific for mutated protein as
demonstrated by immuno-histochemistry, immuno-precipi-
tation and immuno-blotting techniques (Gannon et al., 1990).
It does not bind normal p53 whereas many other monoclonal
antibodies to p53 bind both normal and mutated p53. Sec-
tions were incubated at room temperature for 30 min with
PAb240 as neat supernatant. NCL-CBl (Novocastra Labor-
atories) was raised against a synthetic peptide from the
C-terminal end of the predicted c-erbB-2 protein amino-acid
sequence (Corbett et al., 1990); culture medium diluted 1:40
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was incubated with sections at 4°C overnight. EGFR1
(Amersham International plc) recognises an epitope on the
external domain of the EGFr (Waterfield et al., 1982) and
was applied at a dilution of 1:40 for 30 min at room temper-
ature. After incubation with primary antibody, sections were
washed in tris-phosphate buffered saline (TBS) and covered
with peroxidase-conjugated rabbit anti-mouse immuno-glo-
bulin (Dakopatts) diluted 1:20 for 30 min. The peroxidase
reaction was developed using diaminobenzidine as chromo-
gen and sections were counterstained with haematoxylin. In
addition, 20 further sections were stained with monoclonal
antibody PAbi 801 (Oncogene Sciences) which binds to both
mutated and normal p53 protein; it is specific for a denatura-
tion resistant epitope between amino acids 32-79.
Sections of appropriate control material were included
with each staining run: a squamous cell carcinoma of the
bronchus known to show intense nuclear staining with
PAb240, a breast carcinoma with approximately 15-fold
amplification of the c-erbB-2 gene for NCL-CB1 and nor-
mal human skin and placenta for EGFR1. For each run,
negative controls were prepared by staining duplicate sections
for each tumour using the methods described above, but
omitting the primary antibody. For occasional smaller
tumours, insufficient tissue of suitable quantity was available
to permit staining for p53 (three cases), EGFr (one case) or
c-erbB-2 (one case).
Tumours were scored by assessing both the intensity of
staining (on a four point scale: zero, weak, moderate, strong)
and its extent (focal or diffuse). For the purpose of analysing
the relationship between variables in the present study,
tumours showing at least focal staining of moderate and
strong staining intensity were taken as positive. Statistical
analysis was performed by means of Chi square tests or
Fisher's exact test.
EGFR1 (regarded as positive for the EGFr) was found in 25
of 81 tumours (31%) and weak staining was observed in a
further 43 tumours (53%).
Relationships among tumour stage, grade, p53, the EGFr and
c-erbB-2
Strong or moderate positive staining for p53 or the EGFr
was associated significantly with muscle invasion and high
tumour grade (poor differentiation; Tables I and II).
Complete data on tumour grade, stage and staining for
p53, c-erbB-2 and the EGFr were available in 77 tumours.
Combined staining for either p53 or the EGFr or both was
strongly associated with stage and grade. Thirty-three of the
77 tumours invaded muscle and 28 of the 33 (85%) were
stained positively for either p53 or the EGFr (Table III).
On the other hand, only six of 44 superficial tumours (16%)
were stained positively for either p53 or the EGFr (Table
III). This difference was highly significant (Chi-square = 31.6;
P<0.0001). Of the 78 tumours in which data were available
for p53 and the EGFr, positive staining for p53 and/or the
EGFr was found in 28 of 34 (82%) poorly differentiated
tumours, but only in seven of 44 moderately differentiated
tumours (16%; Chi-square = 31.6; P<0.0001).
On the other hand, the association between staining for
c-erbB-2 and tumour stage was weak: eight of 32 invasive
tumours (25%) and four of 48 superficial tumours were
c-erbB-2 positive (8%; Fisher's exact test = 0.057). No cor-
relation was found between c-erbB-2 and histological grade.
There was also a weak positive association between p53
positivity and positive staining for c-erbB-2. Five of 13
tumours (38%) which were positively stained for c-erbB-2
were also p53 positive compared with only nine of 68 c-erbB-
2 negative tumours (13%; Fisher's exact test = 0.043). No
evidence was found of co-expression of p53 protein and
EGFr (P = 0.99) or EGFr and c-erbB-2 protein (P = 0.75).
Results
Stainingfor p53
Staining of strong or moderate intensity was found in 14 of
79 tumours (18%), weak staining was found in a further 29
cases (36%: total positive cases = 54%). Staining was identi-
fied in cell nuclei and had a diffuse, granular or clumped
appearance, depending on the quality of the nuclear chro-
matin. No cases were seen of only cytoplasmic staining.
There was no appreciable staining of stromal or inflam-
matory cells or non-dysplastic transitional cell urothelium.
Twenty of the tumours (six strong or moderately positive;
three weakly positive and 11 negative with PAb240) were
studied with antibody PAbl801 which stains normal and
mutated p53. There was a good correlation between the two
antibodies: six of the 20 being strongly or moderately
positive with PAb240 and seven of 20 being strongly or
moderately positive with PAbI801. The 45% of tumours
being positive with PAb240 remained positive, but three
additional negative tumours stained giving an overall positive
rate of 60% with PAbl801. The details were as follows: five
of the six strongly or moderately positive tumours remained
strongly or moderately positive and one was weakly positive
on staining with PAbl801. Of the three weakly positive
tumours, one became negative, one became moderately posi-
tive and one remained weakly positive on staining with
PAbI801. Of the 11 negative tumours, one became moder-
ately positive and two became weakly positive.
Discussion
Mutation of the p53 gene appears to be the commonest
mutation yet found - being identified in about 50% of a
variety of human tumours including breast (Cattoretti et al.,
1988), colon (van den Berg et al., 1989) and lung (Iggo et al.,
1990). The present study provides evidence of strong staining
Table I Correlation oftumour stage with strong ormoderate staining
for p53 or EGFr
p53 EGFr
-ve +ve -ve +ve
Superficial tumours (pTa, pTI) 44 1 42 5
Invasive tumours (T2, T3, T4) 21 12 13 20
Chi-square = 13.6 (P<0.001); Chi-square = 20.3 P<0.001)
Table II Correlation of differentiation of the tumour with strong or
moderate staining for p53 and EGFr
p53 EGFr
-ve +ve -ve +ve
Well + moderate 43 2 42 5
Poor 22 12 14 20
Chi-square = 10.6 (P<0.005); Chi-square = 19.3 (P<0.001)
Stainingfor c-erbB-2 and the EGFr
Previous studies have shown that both EGFR1 and NCL-
CBII may produce a combination of both cytoplasmic and
membrane staining, but in the present study, only membrane
staining was assessed. Strong or moderate staining with
NCL-CBII (regarded as positive for c-erbB-2) was observed
in 12 of 81 tumours (15%) and weak staining observed in a
further 19 tumours (23%). Strong or moderate staining with
Table III Relationship between strong and moderate staining for p53
and the EGFr in 33 muscle invasive and 44 superficial tumours
Invasive (n = 33) Superficial (n = 44)
p53 p53
-ve + ve -ve + ve
-ve 5 8 -ve 38 1
EGFr EGFR
+ve 16 4 +ve 5 0p53, c-erbB-1, c-erbB-2 IN HUMAN BLADDER CANCER 969
in 18% of primary human transitional cell carcinomas of the
bladder with weaker staining found in a further 36%.
Allelic deletion of chromosome 17 p has been demonstrat-
ed in human tumours, including bladder cancers (Yokota et
al., 1987; Vogelstein et al., 1988; Mackay et al., 1988; Tsai et
al., 1990) and such deletion is frequently accompanied by
mutation of the remaining allele (Baker et al., 1989; Nigro et
al., 1989; Takahasi et al., 1989). Iggo and colleagues found
single point mutations in p53 messenger RNA in each of
three lung cancers showing immuno-histochemical evidence
of increased p53 protein expression (Iggo et al., 1990). This
evidence is consistent with previous observations that muta-
tion of the p53 protein is usually associated with an increased
half-life in rodents (Jenkins & Sturzbecher, 1988). A large
number of different point mutations have been observed in
the p53 gene (Nigro et al., 1989) and the monoclonal anti-
body PAb240 identifies many, but not all, of these mutations
(Bartek et al., 1990; Rodrigues et al., 1990). It is therefore
likely that some mutated copies of p53 were not detected by
our study. There is good evidence that positive staining with
PAb240 is a specific sign of mutated p53 as this antibody
binds to a variety of mutants in which there is a common
conformational change in the protein (Gannon et al., 1990;
Bartek et al., 1990; Rodrigues et al., 1990). However, there is
also evidence that certain mutants do not carry an exposed
PAb240 epitope (Rodrigues et al., 1990).
It seems likely that similar mechanisms underly our present
observations in bladder cancer. Determination of the exact
incidence of point mutations of the p53 gene in bladder
cancer will probably involve sequencing techniques. Eighteen
per cent of bladder tumours expressed p53 protein strongly
in the present study, but a further 36% exhibited weakly
positive staining giving a total of 54% positively stained.
Further molecular biological studies will be necessary to
clarify the significance of this weak positive staining, but it is
likely that these weakly positive tumours also contain muta-
ted p53, as variation in staining intensity has been noted
previously even in cells known to contain mutated p53. How-
ever, from recent studies ofcolo-rectal cancer, it is also likely
that a further number of the negatively stained tumours will
contain mutated p53 protein in which the PAb240 epitope
has not been exposed (Rodrigues et al., 1990). Interestingly,
we found a significant association between strong or moder-
ate staining and muscle invasion suggesting that tumours
with a high risk of progression may contain high levels of
mutated p53 protein. One may speculate from the clinical
point of view that such high intensities of staining may
provide useful prognostic information.
It is possible that other antibodies which bind to different
epitopes of the p53 protein may prove useful in identifying
the mutations in p53 which do not produce the conforma-
tional changes identified by PAb240. However, previous
studies using PAbl801 and PAb240 have shown similar pat-
terns of staining (Bartek et al., 1990; Rodrigues et al., 1990).
In the present study, we also found broadly similar patterns
of staining - a similar number being strongly or moderately
positive with each antibody, although PAbl8Ol stained a few
more tumours weakly positive.
Determination of quantitative or qualitative changes in the
expression of oncogenes and their protein products might
prove of clinical use in classifying tumours into different
prognostic categories given that such changes at the cellular
level may lead directly to alterations in tumour behaviour.
Such information might well supplement traditional prognos-
tic factors such as tumour grade and stage - indeed this has
been shown to be the case in bladder cancer for the EGFr
(Neal et al., 1990) and in breast cancer for the EGFr and
c-erbB-2 (Sainsbury et al., 1987; Wright et al., 1989). No
correlation was found in the present study between expres-
sion of p53 and the EGFr in contrast to a previous study of
breast cancer (Cattoretti et al., 1988) which used a different
antibody against p53. On the other hand, 85% of the muscle
invasive cancers in our study were stained positively for the
EGFr and/or p53 and the muscle invasive group included all
four double positive tumours. Obviously, it will be of interest
to follow-up this cohort of patients to determine future
clinical behaviour, particularly in the few patients with
invasive disease who are negative for both p53 and the EGFr
and with superficial tumours which are positive for p53 or
the EGFr.
In an initial investigation of 44 patients, positive staining
(of all intensities) for the c-erbB-2 protein product was
observed in 36% (Wright et al., 1990), although a previous
study found little evidence of increased c-erbB-2 expression
using paraffin embedded material and a different antibody
(McCann et al., 1990). The mechanisms underlying over-
expression of c-erbB-2 in bladder cancer are unclear, but in
cancers of the breast and ovary it is associated with gene
amplification (Venter et al., 1987; Gusterson et al., 1988;
Slamon et al., 1989), and a poor clinical outcome. The weak
correlation found between expression ofc-erbB-2 and tumour
stage in the present study of bladder cancer does not exclude
a potential role as a prognostic factor, for in breast cancer
also, no consistent correlation has been found despite a
strong association between c-erbB-2 expression and poor sur-
vival (Barnes, 1989).
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